Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
[Preprint]. 2020 Apr 3:2020.04.01.20049767.
doi: 10.1101/2020.04.01.20049767.

Intervention Serology and Interaction Substitution: Modeling the Role of 'Shield Immunity' in Reducing COVID-19 Epidemic Spread

Affiliations

Intervention Serology and Interaction Substitution: Modeling the Role of 'Shield Immunity' in Reducing COVID-19 Epidemic Spread

Joshua S Weitz et al. medRxiv. .

Update in

  • Modeling shield immunity to reduce COVID-19 epidemic spread.
    Weitz JS, Beckett SJ, Coenen AR, Demory D, Dominguez-Mirazo M, Dushoff J, Leung CY, Li G, Măgălie A, Park SW, Rodriguez-Gonzalez R, Shivam S, Zhao CY. Weitz JS, et al. Nat Med. 2020 Jun;26(6):849-854. doi: 10.1038/s41591-020-0895-3. Epub 2020 May 7. Nat Med. 2020. PMID: 32382154 Free PMC article.

Abstract

The COVID-19 pandemic has precipitated a global crisis, with more than 690,000 confirmed cases and more than 33,000 confirmed deaths globally as of March 30, 2020 [1-4]. At present two central public health control strategies have emerged: mitigation and suppression (e.g, [5]). Both strategies focus on reducing new infections by reducing interactions (and both raise questions of sustainability and long-term tactics). Complementary to those approaches, here we develop and analyze an epidemiological intervention model that leverages serological tests [6, 7] to identify and deploy recovered individuals as focal points for sustaining safer interactions via interaction substitution, i.e., to develop what we term 'shield immunity' at the population scale. Recovered individuals, in the present context, represent those who have developed protective, antibodies to SARS-CoV-2 and are no longer shedding virus [8]. The objective of a shield immunity strategy is to help sustain the interactions necessary for the functioning of essential goods and services (including but not limited to tending to the elderly [9], hospital care, schools, and food supply) while decreasing the probability of transmission during such essential interactions. We show that a shield immunity approach may significantly reduce the length and reduce the overall burden of an outbreak, and can work synergistically with social distancing. The present model highlights the value of serological testing as part of intervention strategies, in addition to its well recognized roles in estimating prevalence [10, 11] and in the potential development of plasma-based therapies [12-15].

PubMed Disclaimer

Figures

FIG. 1:
FIG. 1:
Simplified schematic of intervention serology via shield immunity. (Top) Population dynamics of susceptible, infectious, and recovered in which recovered individuals reduce contact between susceptible and infectious individuals. Arrows denote flows between population level-compartments. (Bottom) Individual view of baseline scenario and shielding scenario, in which the identification, designation, and deployment of recovered individuals is critical to enabling S-R and IR interactions to replace S-I interactions. Bonds denote interactions between individuals. In the Shield Immunity panel, the icon in the recovered individuals denotes the identification of individuals with protective antibodies, and hence the enhanced contribution of such individuals to shield immunity in contrast to the Baseline panel.
FIG. 2:
FIG. 2:
Shield immunity dynamics in a SIR model. (Top) Infectious case dynamics with different levels of shielding, α. (Bottom) Final state of the system as a function of α. In both panels, β = 0.25 and γ = 0.1.
FIG. 3:
FIG. 3:
COVID-19 dynamics in a baseline case without interventions compared to two shield immunity scenarios, α = 2 and α = 20, including deaths, ICU beds needed, and age distribution of fatalities. See the SI for more details on alternative scenarios, high (left) and low (right).
FIG. 4:
FIG. 4:
Impacts of combined interventions of shielding and social distancing in the high scenario. (Left) Fractional reduction in deaths compared to baseline; (Right) Peak level of ICU beds needed on a given day during the epidemic; the red line denotes 25 ICU beds per 100,000 individuals as a demarcation point for surge capacity.

References

    1. Fauci A. S., Lane H. C. & Redfield R. R. Covid-19 – navigating the uncharted. New England Journal of Medicine (2020). URL 10.1056/NEJMe2002387 - DOI - PMC - PubMed
    1. Li Q. et al. Early transmission dynamics in Wuhan, China, of novel Coronavirus-infected pneumonia. New Eng land Journal of Medicine 382, 1199–1207 (2020). URL 10.1056/NEJMoa2001316 - DOI - PMC - PubMed
    1. Zhou P. et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 270–273 (2020). - PMC - PubMed
    1. World Health Organization: Coronavirus disease 2019 (COVID-19) Situation Report - 70 (2020). URL https://www.who.int/docs/default-source/coronaviruse/situation-reports/2....
    1. Ferguson N. et al. Impact of non-pharmaceutical interventions (npis) to reduce COVID19 mortality and healthcare demand (2020). URL https://www.imperial.ac.uk/media/imperial-college/medicine/sph/ide/gida-.... - PMC - PubMed

Publication types